The Supreme Court Just Struck Down Trump's IEEPA Tariffs — But the Trade War Is Far From Over

What Did the Supreme Court Rule?

In a landmark 6-3 decision on February 20, 2026, the Supreme Court ruled that the International Emergency Economic Powers Act (IEEPA) does not authorize the President to impose tariffs. The ruling effectively struck down the sweeping tariffs that President Trump had imposed on key trading partners including China, the EU, and Mexico throughout 2025, which had pushed the average effective US tariff rate from 2.2% under Biden to approximately 13-17% by early 2026.

Within days, US Customs and Border Protection halted tariff collections effective February 24, 2026. Estimates of tariffs already collected range from $130 billion to more than $175 billion, with refunds now flowing through a new CBP portal for qualifying importers. The ruling was a major constitutional check on executive power over trade policy.

How Did Trump Respond?

The administration moved with remarkable speed. On the same day as the Supreme Court ruling, President Trump imposed a new 10% global baseline tariff under Section 122 of the Trade Act of 1974 — a different legal authority that the Court had not addressed. The following day, he raised it to the statutory maximum of 15%. On April 2, 2026, Trump announced additional tariffs under Section 232 of the Trade Expansion Act: restructured duties on steel, aluminum, and copper, plus tariffs of up to 100% on patented pharmaceutical imports.

The result is a tariff regime that, while legally different from the IEEPA tariffs, achieves many of the same economic effects. The Penn Wharton Budget Model estimates the current effective tariff rate at approximately 10.3% — lower than the pre-ruling peak but still dramatically higher than historical norms.

What Has Been the Economic Impact?

The tariff whiplash has created significant economic uncertainty. The S&P 500 shed hundreds of points in the weeks following the initial IEEPA tariffs, and the Nasdaq entered correction territory. While markets have since recovered — the S&P 500 hit a record 7,126 on April 17, 2026 — the recovery has been uneven. Industrials and semiconductors have outperformed, while rate-sensitive real estate and long-duration tech growth names have lagged.

On the consumer side, the tariffs have contributed to sticky inflation. Core PCE remains elevated at 2.4%, above the Fed's 2% target, and consumer prices for imported goods have risen measurably. The EU has prepared $108 billion in retaliatory tariffs, and China faces additional anti-dumping duties, creating a multi-front trade conflict that shows no signs of resolution.

How Should Investors Position?

The trade war creates both risks and opportunities. Companies with primarily domestic revenue streams — utilities, healthcare, and domestic-focused industrials — are relatively insulated. Export-heavy companies, particularly in technology and agriculture, face margin pressure from both tariffs and retaliatory measures. The pharmaceutical sector faces the most dramatic impact from the 100% tariff on patented imports, which could reshape the entire industry's supply chain.

For portfolio positioning, consider overweighting domestic small-caps (Russell 2000) which benefit from trade protection, and underweighting multinational mega-caps with significant overseas revenue. Treasury bonds remain attractive as a hedge against trade-war-induced recession risk, and gold continues to benefit from dollar weakness and geopolitical uncertainty.

The Bottom Line

The Supreme Court's IEEPA ruling was a constitutional milestone, but it hasn't ended the trade war — it's merely shifted the legal basis. With Section 122 and Section 232 tariffs now in place, pharmaceutical tariffs of up to 100%, and retaliatory measures from the EU and China, the global trade landscape remains deeply uncertain. Investors should expect continued volatility around trade policy announcements and position portfolios for a world where higher tariffs are the new normal.